Novel 3-((2-chloroquinolin-3-yl)methylene)indolin-2-one derivatives produce anticancer efficacy in ovarian cancer in vitro

Chandrabose Karthikeyan; Haneen Amawi; Charles R. Ashby; Vishwa M. Khare; Veronica Jones; N. S. Hari Narayana Moorthy; Piyush Trivedi; Amit K. Tiwari

doi:10.1016/j.heliyon.2019.e01603

Novel 3-((2-chloroquinolin-3-yl)methylene)indolin-2-one derivatives produce anticancer efficacy in ovarian cancer in vitro

Chandrabose Karthikeyan
, Haneen Amawi
, Charles R. Ashby
, Vishwa M. Khare
, Veronica Jones
, N. S. Hari Narayana Moorthy
, Piyush Trivedi
, Amit K. Tiwari

Indira Gandhi National Tribal University
Rajiv Gandhi Technical University
University of Toledo
Yarmouk University
St. John's University
University of Pennsylvania
Tuskegee University College of Veterinary Medicine
Bharati Vidyapeeth University

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

A novel series of 3-((2-chloroquinolin-3-yl)methylene)indolin-2-ones were synthesized, using the ‘molecular hybridization approach’ and evaluated for anticancer efficacy. Eleven 3-((2-chloroquinolin-3-yl)methylene)indolin-2-ones (LM01 to LM11)were synthesized and evaluated for in vitro cytotoxic efficacy in cancer (ovarian, prostate and colon)and two non-cancerous cell lines. Among the 3-((2-chloroquinolin-3-yl)methylene)indolin-2-one derivatives, LM08, with a 6-Cl substitution in the 3-quinolinyl moiety, had selective and potent cytotoxic efficacy in the ovarian cancer cell line A2780. Further mechanistic investigations indicated that LM08 significantly inhibited the clonogenic survival of A2780 cancer cells, which was mediated by inducing apoptosis.

Original language	English
Article number	e01603
Journal	Heliyon
Volume	5
Issue number	5
DOIs	https://doi.org/10.1016/j.heliyon.2019.e01603
State	Published - May 2019
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Natural product chemistry
Pharmaceutical chemistry
Pharmaceutical science

Access to Document

10.1016/j.heliyon.2019.e01603

Cite this

@article{0b7961c1e31441829c8f0cf665e1814c,

title = "Novel 3-((2-chloroquinolin-3-yl)methylene)indolin-2-one derivatives produce anticancer efficacy in ovarian cancer in vitro",

abstract = "A novel series of 3-((2-chloroquinolin-3-yl)methylene)indolin-2-ones were synthesized, using the {\textquoteleft}molecular hybridization approach{\textquoteright} and evaluated for anticancer efficacy. Eleven 3-((2-chloroquinolin-3-yl)methylene)indolin-2-ones (LM01 to LM11)were synthesized and evaluated for in vitro cytotoxic efficacy in cancer (ovarian, prostate and colon)and two non-cancerous cell lines. Among the 3-((2-chloroquinolin-3-yl)methylene)indolin-2-one derivatives, LM08, with a 6-Cl substitution in the 3-quinolinyl moiety, had selective and potent cytotoxic efficacy in the ovarian cancer cell line A2780. Further mechanistic investigations indicated that LM08 significantly inhibited the clonogenic survival of A2780 cancer cells, which was mediated by inducing apoptosis.",

keywords = "Natural product chemistry, Pharmaceutical chemistry, Pharmaceutical science",

author = "Chandrabose Karthikeyan and Haneen Amawi and Ashby, \{Charles R.\} and Khare, \{Vishwa M.\} and Veronica Jones and \{Hari Narayana Moorthy\}, \{N. S.\} and Piyush Trivedi and Tiwari, \{Amit K.\}",

note = "Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = may,

doi = "10.1016/j.heliyon.2019.e01603",

language = "English",

volume = "5",

journal = "Heliyon",

issn = "2405-8440",

publisher = "Elsevier Ltd",

number = "5",

}

TY - JOUR

T1 - Novel 3-((2-chloroquinolin-3-yl)methylene)indolin-2-one derivatives produce anticancer efficacy in ovarian cancer in vitro

AU - Karthikeyan, Chandrabose

AU - Amawi, Haneen

AU - Ashby, Charles R.

AU - Khare, Vishwa M.

AU - Jones, Veronica

AU - Hari Narayana Moorthy, N. S.

AU - Trivedi, Piyush

AU - Tiwari, Amit K.

PY - 2019/5

Y1 - 2019/5

N2 - A novel series of 3-((2-chloroquinolin-3-yl)methylene)indolin-2-ones were synthesized, using the ‘molecular hybridization approach’ and evaluated for anticancer efficacy. Eleven 3-((2-chloroquinolin-3-yl)methylene)indolin-2-ones (LM01 to LM11)were synthesized and evaluated for in vitro cytotoxic efficacy in cancer (ovarian, prostate and colon)and two non-cancerous cell lines. Among the 3-((2-chloroquinolin-3-yl)methylene)indolin-2-one derivatives, LM08, with a 6-Cl substitution in the 3-quinolinyl moiety, had selective and potent cytotoxic efficacy in the ovarian cancer cell line A2780. Further mechanistic investigations indicated that LM08 significantly inhibited the clonogenic survival of A2780 cancer cells, which was mediated by inducing apoptosis.

AB - A novel series of 3-((2-chloroquinolin-3-yl)methylene)indolin-2-ones were synthesized, using the ‘molecular hybridization approach’ and evaluated for anticancer efficacy. Eleven 3-((2-chloroquinolin-3-yl)methylene)indolin-2-ones (LM01 to LM11)were synthesized and evaluated for in vitro cytotoxic efficacy in cancer (ovarian, prostate and colon)and two non-cancerous cell lines. Among the 3-((2-chloroquinolin-3-yl)methylene)indolin-2-one derivatives, LM08, with a 6-Cl substitution in the 3-quinolinyl moiety, had selective and potent cytotoxic efficacy in the ovarian cancer cell line A2780. Further mechanistic investigations indicated that LM08 significantly inhibited the clonogenic survival of A2780 cancer cells, which was mediated by inducing apoptosis.

KW - Natural product chemistry

KW - Pharmaceutical chemistry

KW - Pharmaceutical science

UR - https://www.scopus.com/pages/publications/85065551073

U2 - 10.1016/j.heliyon.2019.e01603

DO - 10.1016/j.heliyon.2019.e01603

M3 - Article

AN - SCOPUS:85065551073

SN - 2405-8440

VL - 5

JO - Heliyon

JF - Heliyon

IS - 5

M1 - e01603

ER -

Novel 3-((2-chloroquinolin-3-yl)methylene)indolin-2-one derivatives produce anticancer efficacy in ovarian cancer in vitro

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this